CRx-102 Osteoarthritis Multicenter Evaluation Trial
Summary
CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug dipyridamole and a very low dose of the glucocorticoid prednisolone. CRx-102 is believed to work through a novel mechanism of action in which dipyridamole selectively amplifies the anti-inflammatory and immunomodulatory activities of the glucocorticoid without replicating the dose-dependent adverse effects. CRx-102 has been associated with clinical benefit in proof of concept studies in subjects with hand OA and RA. This is the first study to explore the efficacy of CRx-102 in knee OA. It is considered a dose-finding study and will also compare the potential benefits of CRx-102 treatment to both prednisolone administered alone and to placebo in this indication.
Timeline
- Start
- 2007-08
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dipyridamole | Other / unclassified | 90 mg | — |
| Subject | Dipyridamole | Other / unclassified | 180 mg | — |
| Subject | Dipyridamole | Other / unclassified | 360 mg | — |
| Comparator | Prednisolone | Other / unclassified | 2.7 mg | — |